Questions related to Hematological Malignancies
Blood cancer is a very dangerous disease. Blood can circulate to all parts of the body. Blood cells are generated in the bone marrow. So I decided that I work on both blood and bone cancer and collectively hybrid cancer. I need data set of both of these types of blood cancer collectively or separately. I want to research the base of genes by the use of Artificial Neural Networks
I want to base my research on some procedures of reducing the cost of the treatment of blood cancer. Discussing this with intellects will greatly appreciated
This 15 years old guy presented with left scapular mass 3 years ago , labeled as ewing sarcmoma. He was treated with 14 cession of Ifosfamide- base chemotherapy as well as involved field radiation. However, he developed multiple bone metastasis so the protocol shifted to irrinotecane+vincristine and then gemcitabine+ decetaxel due to stable disease. Despite 4 courses of GemDox protocol his bone metastasis have remained unchanged. what do you advise next for this poor guy?
What are the best functional analyses to prove the pro tumor activity of human neutrophils after isolation from patients with hematological malignancies? We are considering assays to detect Arginase 1, ROS-production or performing co-cultures with autologous t-cells, but thus far have not found any common functional criteria for classification.
I need to recent protocols for bone marrow and peripheral blood culture to perform chromosomal karyotyping analysis in each type of Hematologic malignancies, Can someone help me and send them to me?
Hello everyone! For doing a research I need a dataset including blood cell images of Leukemia (blood cancer) based on leukocytes. There's one dataset "ALL-IDB1" used by Dr. Fabio Scotti in his paper but unfortunately I couldn't get access. Kindly help or guide me if you have a suggestion, thanks!
my review subject is "A review on CAR T-Cells recent progresses in hematological malignancies and solid tumors".
my preference can be journals with good impact factor which do open access and take no charges for publications.
I am about to isolate CD138+ plasma cells using a Miltenyi Biotec MACS kit from the PBMCs of healthy donors.
Although I know that circulating plasma cells are scarce in normal individuals, I need to isolate them to use as control for primary malignant plasma cells that I am working on.
So, I need to know if I can successfully isolate plasma cells from peripheral blood of healthy individuals and the possible yields.
Thank you in advance!
Researches claimed that this blood is more efficient for medical use than blood collected from donors. Patients with rare blood types will benefit the most.
It seems to be very hard to locate the impact factor for The Journal Article, Efficacy and Safety of micafungin versus intravenous itraconazole as empirical anti fungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multi-center study.
Is there a specific source I could utilize to help me find this?
I would like to start with rare mutation detection with ddPCR and I have to deal with a problem of positive control. How can I prepare positive control with certain mutation when I am working with human blood cancer samples? I am looking for rare mutation but I dont have samples with that mutaion in every cell.. Thank you for your advice.
I recently submitted my research for publication on Comparative therapies in AML. Although a different blood cancer than CML, it was concluded that there were no differences seen between the therapies in prognosis of AML. I was wondering if similar results can be seen in CML.
How frequently a blood test (CBC count) should be done in people with various leukemia (ALL, AML, CLL, CML) at remission "to catch up a relapse"? How early in leukemia's manifestation/relapse the WBC anomalies appear?
What is Your experience with sticky platelet syndrome (SPS) ?
SPS, characterized by platelet hyperaggregability has been identified as cause of 21% cases of unexplained arterial and 13,2% of unexplained venous thrombosis.
Do You treat patients with aspirin in first line and clopidogrel as second line treatment, or do You preffer different approach?
There was a phase-2 trial by Roussel et.al in Blood 2010
[Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) ]
which showed CR was higher if velcade was added. But I couldn't find any data on long term outcomes. Is there any data on this?
Dear colleagues , what is your recommendation for a aml young male primary refractory despite salvage regimen with an full match donor.
How I can evaluate patients whom at high risk to get leukemia, , I'm asking about lab technique by which I can expect if patients at risk to be leukemic?
I have a patient with relapsed t-ALL after allogeneic hematopietic stem cell transplantation (AHSCT). She had received hyper-CVAD, Nelarabine, ICE and PEG-Asparaginase before we performed AHSCT for her. She presented with axillary and inguinal lymphadenopathy about day +45 after AHSCT, and lymph node core biopsy showed t-ALL. I have started an accelerated tapering of her Prograf, and I would like to administer chemotherapy before giving donor lymphocyte infusion (DLI) to her.
Please let me know of methods & protocols required for the isolation of pure individual subsets of lymphocytes like B,T,NK & Plasma Cells from lymphocytes of blood. Isolation of Lymphocytes from blood is easy but how to further isolate its subtypes. Please suggest some protocols for that. Thank You.
During anticancer chemotherapy, which usually involves DNA alkylating or intercalating agents, the patients become at higher risk of infection due to reduction of the WBC count, and damage to physical barrier. So, it is likely for the patient to easily get infected, specially in leukemia. Why the DNA acting antineoplastic drugs don't protect him from bacterial and fungal infection, why they don't act on the DNA of these microbes as they act on human cells.
Hematological reference values, is the measurement of majority normal individuals.
In medical labs, we consider that as a (reference) value to measure the abnormality.
Is anyone aware of similar papers or data discussing an increased risk of hematologic malignancies and radiation exposure among interventional radiologists, cardiologists, neuro interventionlists, electrophysiologists, vascular surgeons, or other health care professionals with frequent exposure to radiation in the angiography suite?
Also is anyone aware of any current or pending litigation regarding this possible increased risk, especially in light of recent evidence of premature cataract formation in Interventional cardiologists and Interventional radiologists as well as the rapid transition from a self employed or group physician model to an employee model /integrated health care system /vertical integration?
I am testing translocation of protein from the cytoplasm to the nucleus, I've got a lot of background nuclear fluorescence despite that I used 0.3M glycine in the blocking buffer.
Concerning (mono-)clonal B-cell lymphocytosis with a lymphoma fenotype: from a research perspective, would it not be necessary to perform a bone marrow biopsy in order to exclude lymphoplasmacytic lymphoma? The MYD88 L265P mutation is closely related but does not exclude all cases of LPL.
Erythrocyte microRNA in MDS?
Does anyone know or is there any study which microRNAs might occur as overexpresed in erythrocyte in some supgroup of myelodysplastic syndrome?